Shield

STX.L

Tags: GB Healthcare Drug Manufacturers - Specialty & Generic

Shield Therapeutics plc Price (STX.L)

Stock Price

Low: Year Low

High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Shares Outstanding

722,544,000

(209.8521)%

Market Cap of Shield (STX.L)

Market cap:

As of , STX.L has a market cap of . This makes STX.L the 877th most valuable company in the GB by market cap. Market capitalization, or market cap, is the total value of a company's outstanding shares of stock, calculated by multiplying the current stock price by the total number of shares.

Year

Beginning Of Year

End Of Year

YOY Change

Community Sentiment 0 votes

↑ 0% ↓ 0%

Description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gat... Read More

Sector: Healthcare

Previous Close Fetching Data...
Range $0.0249-5.87
Market Cap 31.77M
Enterprise Value No Data
Avg Volume Fetching Data...
P/E Ratio Fetching Data...
Dividend Yield Fetching Data...

Industry: Drug Manufacturers - Specialty & Generic

ceo: Mr. Anders Lundstrom
IPO Date: February, 26, 2016
Country: GB
Currency: GBp
Headquaters: No Data
Employees: 73

- Revenue from each product or segment:

Product or Segment	Value:	% - Total	Last 3Y:

- Revenue by Region

Product or Segment	Value:	% - Total	Last 3Y: